ClinicalTrials.gg
CompletedNCT06795165Updated Aug 12, 2025

Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

A Phase 4 interventional study of Moxidectin 2 MG Oral Tablet and Placebo in Blepharitis, sponsored by Eye Research Foundation, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Eye Research Foundation, Inc. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Blepharitis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Blepharitis · United States.

Enrollment
29th of 37
24 · median 60
Started
2025
with 1 other
Phase 4
11 of 39
1 open now
Registered
35th of 39
by date
Lead sponsor
1 of 39
Eye Research Foundation, Inc.

Among the 39 studies in Blepharitis with a site in United States, this one is the 29th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 in phase 4, and was the 35th registered.

Blepharitis

73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.

Browse Blepharitis studies →

Open to participants now

5 of the 39 studies in Blepharitis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Blepharitis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Blepharitis with a site in United States, or all of them as a file.
02

Study summary

A Single-Center, Investigator-Masked, Randomized, Placebo-Controlled, Investigator Initiated Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

03

Conditions studied

  • Blepharitis

Browse trials for

Keywords

  • blepharitis
  • demodex
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Active blepharitis with collarettes

Exclusion criteria

Exclusion Criteria:

  • Other eye disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Active

    Drug: Moxidectin 2 MG Oral Tablet

  • Experimental
    Active and Placebo

    Drug: Moxidectin 2 MG Oral Tablet · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Collarette count

    Collarette Count

    Time frame: 6 weels

07

Study locations

1 site
  • Eye Research Foundation, Inc.
    Newport Beach, California 92663, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Apr 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 27, 2025
StartActual
Feb 2, 2025
Primary completionActual
Apr 28, 2025
CompletionActual
Jun 15, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06795165
Lead sponsor
Eye Research Foundation, Inc.
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Feb 2, 2025
Primary completion
Apr 28, 2025
Completion
Jun 15, 2025
Last update
Aug 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxidectin

Start the discussion